Navigation Links
Stonegate Report About Unigene Laboratories Inc.
Date:3/13/2008

ral and administrative costs should show minimal increases for the last quarter of FY07 and throughout FY08.

Importantly, Unigene restructured its loan obligations earlier this year in May 2007 and eliminated its "going concern" status. The loans are primarily from officers and total approximately $16 million. They are now recast over eight years at 9 percent interest with no payments due (interest will accrue) for the first three years and no prepayment penalties.

With Fortical gaining market share, an advancing pipeline targeting large markets, a near-term positive bottom line, and huge upside potential, we believe that Unigene represents a significant opportunity for investors.

Risks

UGNE currently has only one product on the market. Any changes in market demand, USL's ability to market the product, any regulatory changes, or any delays in production would have a significant negative impact on the Company.

UGNE has products in its pipeline in various stages of development; however, Unigene may never develop another product that receives regulatory approval.

Unigene has incurred significant operating losses since its inception. The most recent quarter (September 2007) showed an accumulated deficit of $121.6 million. UGNE is dependent on partnerships and collaborations in the development of its pipeline. The Company's inability to establish new partnerships and to maintain current corporate partnerships and licensing arrangements would negatively impact the progress of the Company.

The pharmaceutical industry is extremely competitive in general, and with the aging population swelling the ranks of osteoporosis sufferers, competition in this market has heated up. Unigene competes with large companies with established products and other therapies that may emerge and displace calcitonin.

Indication: The complete report including tables and pictures can be downloaded free of charge as a pdf-file under

SOURCE Unigene Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
2. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Helix BioPharma reports Q2 2008 highlights, financial results
5. Oncothyreon reports full year and fourth quarter 2007 financial results
6. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... third edition of Infusion Nursing: An ... the Infusion Nurses Society (INS), includes Totect(®), the ... are a group of chemotherapy medications including daunorubicin, ... in the treatment of various types of cancer ... to the INS publication: "In September 2007, the ...
(Date:12/14/2009)... CARLOS, Calif., Dec. 14 Nektar Therapeutics ... Winger has been appointed to serve on its ... biopharmaceutical industry leader with over 35 years of ... ,, "Dennis brings to Nektar extensive industry perspective ... said Howard W. Robin, President and CEO of ...
(Date:12/14/2009)... - Results From a Survey Conducted by UCB ... Industrialized Countries , , - A third ... impacts their enjoyment of the festive ... find shopping for gifts, preparing ... difficult to do, - ...
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused ... therapeutics for cardiovascular and muscle disease, today announced ... plays a crucial role in the progression of ... and in neuromuscular synaptic regeneration in mice. ... of the journal Science , reveal miR-206 ...
Breaking Biology Technology:Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2
... its HQ all the way to prison. , ,After a ... of ENWRONG to PRISMA. After paying $665 million in legal fees, ... some of its executives walk to prison. The PRISMA Corporation ... in 25 different business units, a big drop from the 2400 ...
... Communications , a Midwestern company building cross-platform network adapters ... has announced a free trial of its link ... the IEEE 802.3ad standard , combines multiple Ethernet ... the individual ports' bandwidth to produce a high-speed data ...
... of technology-based businesses and jobs in a largely rural part ... last week to support efforts to build an E-Learning industry ... a task force to push for the cluster was unanimously ... the independent, non-profit science and technology adviser to the governor ...
Other Biology Technology:Why is Enron now called Prisma? 2Why is Enron now called Prisma? 3Tech Council passes E-Learning efforts for Northern Wisconsin 2
(Date:12/14/2009)... of Alberta researchers are part of an international team ... fossilized bones, to revise the history of North America,s ... U of A Earth and Atmospheric Sciences professor Duane ... based on radiocarbon dating of bones and teeth. That ... mammals in North America (the ,megafauna,) disappeared about 13,000 ...
(Date:12/14/2009)... AlaskaScientists have identified a novel antifreeze molecule in a ... 100 degrees Fahrenheit. Unlike all previously described biological antifreezes ... little or no protein. It is composed of a ... new places within the cells of organisms. , ... this molecule is a whole new kind of antifreeze ...
(Date:12/14/2009)... transmitted by sneezing, touching, or for Tasmanian devils ... that may have driven the dinosaurs to extinction through ... a member of f1000 Biology, highlights the ,paleobiological detective ... One. This led them to deduce that a protozoan ... seen in many tyrannosaurid fossils. , The parasite,s modern-day ...
Breaking Biology News(10 mins):Scientists isolate new antifreeze molecule in Alaska beetle 2Jerome Bettis Endorses Chews 4 Health Dietary Supplements 58932 1Jerome Bettis Endorses Chews 4 Health Dietary Supplements 58932 2Jerome Bettis Endorses Chews 4 Health Dietary Supplements 58932 3Visiting Nurse Hospice Atlanta Selects PatientPlacement com to Automate Intake and Manage Faxes 58930 1Visiting Nurse Hospice Atlanta Selects PatientPlacement com to Automate Intake and Manage Faxes 58930 2Visiting Nurse Hospice Atlanta Selects PatientPlacement com to Automate Intake and Manage Faxes 58930 3Visiting Nurse Hospice Atlanta Selects PatientPlacement com to Automate Intake and Manage Faxes 58930 4SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites 58928 1SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites 58928 2SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites 58928 3SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites 58928 4
... therapies are beginning to offer new treatment options following ... experts said at the first European Multidisciplinary Conference in ... , "Personalizing therapy is the key strategy for longer ... Kosmidis, head of the second Medical Oncology Department at ...
... evaluating new techniques for early diagnosis and treatment of lung ... on Thoracic Oncology (EMCTO) in Lugano, Switzerland (1-3 May 2009). ... worldwide and also in Europe. One of the reasons for ... lacking or occur only late in the course of the ...
... long ago, were given short shrift as genetic junk. ... in normal functioning as well as diseases such as ... Scientists at Johns Hopkins were surprised to find an ... online April 9 in the Proceedings of the ...
Other Biology News:Personalized treatment for early lung cancer 2Early detection of lung cancer: New data presented at multidisciplinary meeting 2When cells reach out and touch 2When cells reach out and touch 3
...
...
Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag...
... Fixed Angle Rotor for use ... Centra CL3CL3R, and Centra-MP4/MP4R. ... sputum samples and other difficult ... individual aerosol containment. Complete with ...
Biology Products: